Dordaviprone is under clinical development by Chimerix and currently in Phase II for Pheochromocytoma. According to GlobalData, Phase II drugs for Pheochromocytoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dordaviprone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ONC-201 is under development for the treatment of high-grade glioma including thalamus, hypothalamus, brainstem, cerebellum, gliosarcoma, midbrain, or spinal cord, diffuse midline glioma, neuroendocrine tumors, diffuse intrinsic pontine glioma, pheochromocytoma-paraganglioma (PC-PG), triple-negative breast cancer and endometrial, colorectal, prostate cancers, , relapsed or refractory acute myelocytic leukemia, acute lymphocytic leukemia and myelodysplastic syndrome, multiple myeloma. The drug candidate is administered orally. The drug candidate is developed based on cell-based molecular imaging platform. It acts by targeting JAK/STAT pathway, Akt and ERK and ClpP. It was also under development for the treatment of non-small cell lung cancer. It was also under development for the treatment of relapsed/refractory non-Hodgkin's lymphoma includes diffuse large b-cell lymphoma, mantle cell lymphoma, cutaneous T-cell lymphoma and transformed large cell lymphoma.
Chimerix is a biopharmaceutical company. It develops, discovers, and commercializes novel and oral antiviral therapeutics. The company’s pipeline product portfolio includes ONC201, ONC206, ONC212, CMX521 drug candidates. Its products are used to treat various diseases like gliomas, central nervous system tumors, SARS-CoV-2 (COVID-19), and IND-enabling studies. Its brincidofovir tablet and oral suspension formulations are used in the treatment of smallpox disease in adult and pediatric patients. The company markets its products under the brand name of TEMBEXA. The organization works in partnership with Oncoceutics, Inc., Cantex Pharmaceuticals, BARDA, and SymBio Pharmaceuticals. Chimerix is headquartered in Durham, North Carolina, the US.
For a complete picture of Dordaviprone’s drug-specific PTSR and LoA scores, buy the report here.